ERBB2 and neoplasm: The ability of nanoparticles containing a pH sensitive ART derivative to down-regulate HER1, HER2, and HER3, as well as other proteins linked to neoplasia, suggests that this approach has real therapeutic potential for treatment of specific breast cancer subtypes.